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RECOMBINANT MYCOBACTERIA cell wall and act synergistically with other antimicrobial 
OVEREXPRESSING D-ALANINE LIGASE agents (Rastogi et al., 1990). In the early 1970s, David 
GENE AND USES THEREFORE (1971) isolated and characterized step-wise DCS-resistant 
M. tuberculosis mutants that showed either normal or 
CROSS-REFERENCE TO RELATED 5 reduced cellular permeability to DCS and speculated that Alr 
APPLICATIONS plays only a minor role in the mechanism of action of DCS. 
Mycobacterium smegmatis, a nonpathogenic species, is a 
This application is related to U.S. Provisional Application useful model to study drug resistance mechanisms in patho- 
Ser. No. 601434,200, filed on Dec. 17, 2002, which is genic mycobacteria, especially when conserved cellular 
incorporated herein by reference. l o  processes are involved (Reyrat and Kahn, 2001; Tyagi and 
Sharma, 2002). Peteroy et al. (2000) described the isolation 
STATEMENT REGARDING FEDERALLY and characterization of an M. smegmatis mutant resistant to 
SPONSORED RESEARCH OR DEVELOPMENT both DCS and vancomycin though the molecular basis of the 
resistance mechanism remains unknown. In previous stud- 
The present invention was sponsored by the United States 1s ies, we identified a spontaneous DCS-resistant M. smegmatis 
Department of Agriculture under USDA Cooperative State mutant with a promoter-up mutation in the alr gene, result- 
Research Service Project Grant No. NEB 14-108 and the ing in the overproduction of the Alr enzyme (Caceres et al., 
National Institute of Health under contract number R03 1997). Air was shown to be inhibited by DCS in a concen- 
A1051 176-01. The government may have certain rights in tration-dependent manner, and DCS resistance could be 
the invention. 20 conferred to pathogenic mycobacteria carrying the M. smeg- 
matis alr gene in a multicopy plasmid. In addition, DCS was 
BACKGROUND OF THE INVENTION shown to competitively inhibit the native Ddl enzyme from 
M. tuberculosis (David et al., 1969). Belanger et al. (2000) 
The present invention relates to recombinant mycobacte- reported the characterization of a temperature-sensitive M. 
rial strains overexpressing essential biosynthetic enzymes of 25 smegmatis mutant with a single amino acid substitution in 
pathogenic mycobacteria and to methods for using these Ddl. The mutant was more susceptible to DCS, and the 
strains. More specifically, the present invention relates to temperature sensitivity phenotype was due to the decreased 
recombinant mycobacteria strains overexpressing D-alanine activity of the mutated enzyme. 
ligase (Ddl) and the use of such strains in in vitro methods Recently, we observed that M. smegmatis alr null mutants 
for identifying antimycobacterial agents directed against 30 are not dependent on D-alanine for growth, suggesting the 
Ddl. existence of another pathway for D-alanine biosynthesis 
The bacterial cell wall is an ideal target for drug design (Chacon et al., 2002). In addition, the alr null mutant is 
since similar structures and biosynthetic pathways are absent hypersusceptible to DCS, suggesting that a lethal target 
from mammalian hosts. The lipid-rich mycobacterial cell other than Alr is responsible for the bactericidal effect of 
wall acts as an efficient permeability barrier (Brennan and 35 DCS. 
Nikaido, 1995). Peptidoglycan, the backbone of this struc- In order to develop novel antimicrobial agents structurally 
ture, contains the D-amino acids D-alanine, D-glutamate, and related to DCS, the lethal target(s) of DCS need to be 
diaminopimelate, which may contribute to its stability identified and methods of screening for inhibition need to be 
against proteolytic degradation. D-Alanine is one of the developed. 
central molecules of the cross-linking step of peptidoglycan 40 
assembly. Peptidoglycan biosynthesis in mycobacteria fol- BRIEF SUMMARY OF THE INVENTION 
lows pathways similar to those in other eubacteria (Belanger 
and Inamine, 2000). There are three enzymes involved in the In this study, we investigated the roles of both Alr and Ddl 
D-alanine branch of peptidoglycan biosynthesis: the pyri- in the mechanisms of action of and resistance to DCS in M. 
doxal phosphate-dependent D-alanine racemase (Alr), the 45 smegmatis. We demonstrate that Ddl activity is inhibited by 
ATP-dependent D-a1anine:o-alanine ligase (Ddl), and the DCS in a concentration-dependent manner. Overexpression 
ATP-dependent D-a1anine:o-alanine-adding enzyme (MurF) of the ddl gene confers resistance to DCS but not to 
(Walsh, 1989). D-Cycloserine (DCS; 4-amino-3-isoxazolidi- 0-chloro-D-alanine (BCDA), an inhibitor of D-alanine race- 
none) is a rigid analog of D-alanine and targets both Alr and mase. Furthermore, a strain overexpressing both the alr and 
Ddl in Escherichia coli (Lambert and Neuhaus, 1992; Neu- 50 ddl genes displayed an increased level of resistance to DCS. 
haus, 1967). DCS also inhibits Mycobacterium tuberculosis Analysis of the intracellular alanine pools in wild-type and 
Alr and Ddl enzymes (David et al., 1969; Strych et al., recombinant M. smegmatis strains demonstrated that Ddl 
2001), suggesting that both Alr and Ddl are targets of DCS activity is not significantly affected by DCS at concentra- 
in mycobacteria. tions inhibiting Alr. 
DCS is effective against mycobacteria and is recom- 55 The present invention is directed to recombinant myco- 
mended to treat multidrug-resistant M. tuberculosis in the bacterial strains which overproduce D-alanine ligase (Ddl), 
DOTS-Plus management plan (Farmer, 2001; World Health to cloned isolated genes encoding Ddl, and to the uses of the 
Organization, 2000). However, undesirable side effects recombinant strains, and heterologous proteins. 
restrict its use in human chemotherapy (Yew et al., 1993). In one aspect of the present invention, recombinant M. 
Nonetheless, the potent bactericidal effect of DCS against 60 smegmatis strains expressing heterologous or overexpress- 
mycobacteria makes this drug an attractive prototype com- ing native Ddl are provided. In one embodiment of this 
pound to develop novel antimycobacterial agents. In addi- aspect, the Ddl is the product of M. smegmatis ddl gene. In 
tion, identification of the lethal target(s) of DCS action another embodiment, the Ddl is the product of M. tubercu- 
would allow for the rational design of new antimycobacte- losis ddl gene. In yet another embodiment, the Ddl is the 
rial drugs, structurally related or unrelated to DCS, targeting 65 product of both M. smegmatis and M. tuberculosis ddl genes. 
enzymes of the D-alanine pathway of peptidoglycan biosyn- In another aspect of the invention, purified recombinant 
thesis. Moreover, these types of inhibitors may weaken the Ddl is provided. 
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In a further aspect of the invention, cell-free methods for squares), GPM2 (open squares), GPM259 (open triangles), 
screening for antimicrobial agents which target the D-alanine GPM265 (solid triangles), GPM14 (solid diamonds), and 
ligase, an enzyme in the D-alanine branch of mycobacterial GPM260 (open diamonds). Statistical analysis for three 
peptidoglycan synthesis are provided. In one embodiment of independent experiments was performed as described in 
this aspect, the antimicrobial agent is structurally related to 5 Materials and Methods. Susceptibilities to DCS can be 
D-cycloserine. In another embodiment, the antimicrobial divided into four groups (group I, mc2155 and GPM2; group 
agent is unrelated to DCS. In a further embodiment of this 11, GPM259 and GPM265; group 111, GPM14; group IV, 
aspect, the screening method employs a thin-layer chroma- GPM260). Significant differences between groups were 
tography assay to detect Ddl enzyme activity. In yet another detected (group I versus group 11, Pe0.003; group I1 versus 
embodiment, the screening method employs a phosphate 10 group 111, PP0.025; group I11 versus group IV, P=0.020), 
release assay. while no significant differences within groups were detected 
In another aspect of the invention, in vitro methods for (P20.881). 
detecting bactericidal activity of compounds against patho- FIG. 6 shows characteristic HPLC chromatographic pro- 
genic mycobacteria are provided. The methods comprise the files of M. smegmatis intracellular amino acid pools. Intra- 
use of overexpressing recombinant mycobacterial strains In is cellular amino acid pools of M. smegmatis mc2155 untreated 
one embodiment of this aspect, the recombinant mycobac- (A) and treated with DCS (B) were prepared and analyzed 
terial strain is GPM259. In another embodiment, the recom- by a reverse-phase HPLC method as described in Materials 
binant strain is GPM260. In a further embodiment, the and Methods. The synthetic amino acid L-homo-arginine 
recombinant strain is GPM265. (L-hArg) served as an internal standard for quantifying the 
20 abundance of each individual amino acid Peaks for various 
BRIEF DESCRIPTION OF THE DRAWINGS amino acids are indicated, with L- and D-alanine highlighted. 
FIG. 7 shows intracellular pool of alanine in M. smeg- 
FIG. 1 shows primer extension analysis of the M. smeg- matis strains Exponentially growing MJ"smegmatis cells in 
matis and M. tuberculosis ddl transcripts. Total RNA (40 pg) minimal media were split into two subcultures, and DCS 
from mc2155, GPM259, and GPM265 was annealed with 25 was added to a final concentration of 75 pg ml-' to one of 
primer SMDDLPE (A) or TBDDLPE (B) and extended as the subcultures Cells were harvested after 2 h of incubation, 
described in Materials and Methods. Lanes A, C, G, and T and intracellular amino acid pools were determined as 
display a dideoxy sequencing ladder with the corresponding described in Materials and Methods The intracellular pool of 
primer. Asterisks, transcriptional start sites. The p u t a t i v e  alanine (full-length bars) is expressed relative to the 
10 boxes are highlighted. The start codon (GTG) for the M. 30 L-glutamate pool ([AlaliL-Glu]). The relative abundance of 
smegmatis ddl gene is boxed. each stereoisomer in the pool is also shown by open (L-ala- 
FIG. 2 shows autoradiograms of the TLC for typical Ddl nine) and solid (D-alanine) bars and indicated in the table at 
assays. Ddl activities in crude extracts were determined as the bottom. Values shown are meanszstandard deviations of 
described in Materials and Methods. (A) Linear increase in three independent experiments. Analysis of variance was 
the synthesis of the D-a1anine:o-alanine dipeptide at increas- 35 used to compare values for total alanine, L-alanine, and 
ing amounts of GPM259 cell extract. The percentage of D-alanine pools in each strain for both DCS-treated and 
conversion was defined as the percentage of the total radio- untreated cells. Significant differences were observed for the 
activity present in the [14c]o-~la: D-Ala dipeptide spot. (B) L-alanine pools (P=0.03). For D-alanine pools, significant 
Percent inhibition of dipeptide formation (percent inhibi- differences (asterisks) were observed only for strains 
tionP1OO-100x[percent con~ersion,,~~ ,&percent conver- 40 GPM259 (Pe0.05), GPM14 (Pe0.01), and GPM260 
~ i o ~ , ~ ~ , , ~  DCS]) in GPM259 cell extract (8 pg of total (p<0.01). 
protein) at increasing concentrations of DCS. 
FIG. 3 shows analysis of Dir and Alr activities in M. DETAILED DESCRIPTION OF PREFERRED 
smegmatis strains. Specific activities for Ddl (A) andAlr (B) EMBODIMENT 
in crude extracts were determined as described in Materials 45 
and Methods. Specific activities are expressed as micro- D-Cycloserine (DCS) targets the peptidoglycan biosyn- 
moles of substrate (L-alanine for Alr enzyme assay and thetic enzymes D-alanine racemase (Alr) and D-a1anine:o- 
D-alanine for Ddl enzyme assay) per milligram per minute alanine ligase (Ddl). Previously, we demonstrated that the 
(meanszstandard deviations of triplicate measurements). overproduction of Alr in Mycobacterium smegmatis deter- 
FIG. 4 shows inhibitory effect of DCS on M. smegmatis 50 mines a DCS resistance phenotype. As described in further 
Ddl activities. Enzyme activities were determined in cell detail herein, we investigated the roles of both Alr and Ddl 
crude extracts from mc2155 (solid squares), GPM14 (solid in the mechanisms of action of and resistance to DCS in M. 
triangles), GPM259 (open triangles), GPM260 (open smegmatis. It was discovered that the overexpression of 
squares), and GPM265 (solid diamonds) in the presence of either the M. smegmatis or the Mycobacterium tuberculosis 
increasing concentrations of DCS. Percent inhibition was 55 ddl gene in M. smegmatis confers resistance to DCS, but at 
calculated (percent inhibition=lOO-100[SA,,, DcJSA,th,,t lower levels than the overexpression of the alr gene. Fur- 
DCS]; SA, specific activity) from three independent experi- thermore, a strain overexpressing both the alr and ddl genes 
ments. Statistical analysis was performed as described in displayed an eightfold-higher level of resistance. The ala- 
Materials and Methods. The inhibition patterns can be nine pools in M. smegmatis wild-type and recombinant 
divided into two groups (group I, mc2155, GPM14, 60 strains with or without DCS treatment were determined. 
GPM259, and GPM260; group 11, GPM265). A significant Alr-overproducing strain GPM14 cells not exposed to DCS 
difference between groups was detected (P=0.02), while no displayed almost equimolar amounts of L- and D-alanine in 
significant differences within group I were detected the steady state. The wild-type strain and Ddl-overproducing 
(P=0.28). strains contained a twofold excess of L- over D-alanine. In all 
FIG. 5 shows inhibition of colony formation by DCS for 65 strains, DCS treatment led to a significant accumulation of 
various M. smegmatis strains. The curves were generated L-alanine and a concomitant decease of D-alanine, with 
from data of a representative experiment with mc21 55 (solid approximately a 20-fold excess of L-alanine in the Ddl- 
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overproducing strains. These data suggest that Ddl is not These data confirmed that the mycobacterial Ddl enzyme is 
significantly inhibited by DCS at concentrations that inhibit a target of DCS. 
Alr. The present invention is based on the above discoveries 
~~~~~~~~~~~i~~ of either the M, smegmatis or M, tuber- 
which suggest that Ddl is the lethal target of DCS and thus culosis ddl gene, using the same expression vectors as those 
allow for identification of novel drugs targeting the D-alanine 5 used to overexpress (Caceres et al,, 1997), confers an branch of mycobacterial peptidoglycan biosynthesis. intermediate level of resistance to DCS. Furthermore, The publications and other materials used herein to illu- GPM260, a recombinant strain of M. smegmatis overpro- 
minate the background of the invention, and in particular 
cases, to provide additional details respecting the practice, ducing both and Ddl, was constructed and characterized' 
are incorporated by reference and for convenience are 10 GPM260 a higher level resistance DCS than 
referenced in the following text by author and date and are Its parent strain, GPM14, which is consistent with the 
listed alphabetically by author in the appended ~i~~ of increased DCS resistance levels of S. gordonii mutants with 
References. elevated Alr and Ddl activities (Reitz et al., 1967). To test the 
hypothesis that inhibition of Alr by DCS decreases the 
DEFINITIONS 15 intracellular pool of D-alanine, we compared the levels of 
D-alanine pools in wild-type and recombinant M. smegmatis 
The present invention employs the following definitions: strains with or without DCS treatment. The results showed 
"alrK and ‘‘air'' refer to the D-alanine racemase gene, that DCS treatment decreased the intracellular D-alanine 
including normal alleles of the alrA gene. pools in strains with wild-type Alr activity while the Alr- 
"Air" and "Air" refer to o-alanine racemase enzyme. 20 overproducing strain GPM14 maintained a relatively abun- 
''Displays increased susceptibility to antimycobacterial dant pool of D-alanine. This observation is consistent with 
agent" refers to a reduction in the minimal inhibitory con- the intermediate level of resistance to DCS of Ddl-overpro- 
centration of the mutant strain when compared with the wild ducing strains. In addition, analysis of the alanine pools in 
type strain. Alr-Ddl-overproducing strain GPM260 suggests that, upon 
''DCS" and ''~-cycloserine" refer to 4-amino-3-isoxayoli- 25 exposure to DCS, Alr is readily inhibited. In contrast, 
dinone. overproduction of Alr andor Ddl does not have an effect on 
"ddy refers to the o-alanine ligase gene including normal the susceptibility to vancomycin. The increased resistance of 
alleles of the ddl gene. a previously isolated M. smegmatis mutant to both DCS and 
"DdY refers to D-alanine-D-alanine synthetase, which is vancomycin (Peteroy et al., 2000) may underscore a resis- 
also referred to as D-alanine ligase. 30 tance mechanism different from overproduction of Alr a n d  
"Isolatedpolypeptide" refers to a polypeptide produced as Or Ddl. Regarding resistance to DCS, there has been only 
an expression product of an isolated and manipulated one fully characterized mechanism in mycobacteria involv- 
genetic sequence, even if expressed in a homologous cell ing ~verex~ression of the air gene (Caceres et al., 1997). In 
type. Synthetically made forms or molecules expressed by this study, we have shown that overex~ression of the ddl 
heterologous cells are inherently isolated molecules. 35 gene also confers DCS resistance in M. smegmatis, but at 
previous studies, a genomic library from a DCS- levels of resistance below those for strains overproducing 
resistant mutant constructed in a multicopy plasmid was Alr. Therefore, we do not expect that mutational changes, for 
introduced into the wild-type M. smegmatis strain and example, ddl Promoter-up mutations, would play an impor- 
clones resistant to 300 pg of DCS ml-' were selected and tant role in the emergence of naturally DCS-resistant strains. 
isolated (Caceres et al., 1997). Using this strategy, we did 40 The presence of a mutation(s) in the ddl structural gene 
not identify a recombinant clone carrying the ddl gene. Since leading to DCS resistance has not been demonstrated and 
target overproduction determines a drug resistance pheno- needs further investigation. 
type, this Outcome was To any possible DCS targets both Air and Ddl enzymes, but the lethal 
bias in this library, we also screened a M. smegmatis cosmid target for its bactericidal effect has not been identified M, library in a manner. 
a DCS resistant 45 smegmatis null mutants are not dependent on D-alanine 
clone carrying the ddl gene was still not identified. Lowering for growth, indicating that there is another pathway for the DCS concentration resulted in a high background of 
DCS-sensitive colonies. These data suggest that either the D-alanine biosynthesis (Chacon et al., 2002). In addition, the 
overexpression of the ddl gene is toxic to the host or that the M. smegmatis alr mutant is DCS, under- 
level of overexpression is not sufficient to confer a selectable lying the existence of another lethal target, most likely Ddl. 
resistance phenotype under the selection conditions 50 The DCS hypersensitivity phenotype of the air mutant is 
described, T~ test these hypotheses, the M, smegmatis and also consistent with the essentiality of the M. smegmatis ddl 
M. tuberculosis ddl genes were amplified from genomic gene, as s%gested by the temperature sensitivity phenotype 
DNA and cloned into the E. co~i -~ycobac te~ ium shuttle of a mutant carrying a single amino acid substitution in Ddl 
vector pMV262, carrying a kanamycin resistance marker. (Belanger et al., 2000) This temperature-sensitive mutant is 
Recombinant plasmids were introduced into M. smegmatis, 55 also more susceptible to DCS, presumably due to the low 
and kanamycin-resistant transformants were isolated. activity of the mutated Ddl. Therefore, Ddl seems to be the 
In this study, we demonstrated that Ddl enzyme activities lethal target of DCS, while the inhibition of Alr by DCS 
in crude extracts were inhibited by DCS in a concentration- further decreases the D-alanine pool and contributes to the 
dependent manner, similar to the effect observed for the Alr inhibition of Ddl. Previously, it was suggested that DCS 
enzyme (Caceres et al., 1997). Approximately 50% of Ddl 60 resistance in M. tuberculosis is primarily due to mutations in 
enzyme activity is inhibited by DCS at a concentration of the ddl gene (David et al., 1969), and it was further specu- 
200 pg ml, while only 10 to 15% of the Ddl activity is lated that inhibition of Alr plays only a minor role in the 
inhibited at 50 pg ml, near the MIC. The apparent discrep- mechanism of DCS action (David, 1971) Contrary to this, 
ancy reflects the difference between in vivo and in vitro our data showed that Ddl is not significantly affected by 
conditions. In live bacilli, DCS also inhibits Alr, resulting in 65 DCS at the concentration that inhibits Alr. Our observation 
a limited supply of D-Ala, which is the substrate for Ddl, suggests that Alr overproduction contributes to the mainte- 
while in the cell-free assay, D-Ala is provided in excess. nance of the internal D-alanine pool, thus antagonizing the 
7 8 
inhibition of Ddl by DCS. For the Streptococcus faecalis lethal target of the bactericidal action of DCS. Thus, accord- 
enzymes, the DCS inhibition constants for both Alr (Kr=0.02 ing to the present invention, a method is provided for 
mM) and Ddl (Kr=0.9 mM) have been determined from the screening of antimycobacterial agents against Ddl by a 
purified enzymes (Neuhaus, 1967). If the K 3  for the myco- variety of drug screening techniques. 
bacterial enzymes were to follow a similar trend, an attrac- 5 Preferably, purified Ddl is obtained from M. tuberculosis 
tive hypothesis would be that the overproduction of a ddl gene by PCR amplification and cloning into a proper 
high-affinity DCS-binding target (Alr) would protect a more expression shuttle plasmid vector, such as an E. coli expres- 
fundamental and low-affinity target, probably Ddl, from sion vector endowed with a mycobacterial replication origin 
drug inhibition. In this view, the major mechanism of andor promoter, and overexpressed in M. smegmatis. This 
resistance is the overproduction of the high-affinity but l o  host strain is modified by inactivation of its endogenous ddl 
dispensable target, while the bactericidal effect is due to the gene, so that it only expresses the M. tuberculosis counter- 
inhibition of the low-affinity lethal target. Our studies do not part. The M. tuberculosis Ddl enzyme is purified as a 
rule out the possibility that the bactericidal action of DCS polyhistidine-tagged fusion protein through a single-step 
may result from the inhibition of a lethal target(s) other than affinity chromatography in large amount and its identity is 
Ddl. Further research is necessary to assess the lethal targets 1s verified with biochemical methods. Ddl catalyzes the reac- 
in the D-alanine branch of peptidoglycan biosynthesis in tion 2 D-alanine+ATP+o-alanyl-D-alanine+ADP+Pi. Thus 
mycobacteria. This information is necessary for the devel- the purified protein may be used in any of a variety of in 
opment of new antimycobacterial agents targeting the D-ala- vitro cell-free screen systems as are known in the art. 
nine pathway. The thin-layer chromatography (TLC)-based D-alanine 
The practice of the present invention employs, unless 20 ligase assay described in Example 1 can be used, however 
otherwise indicated, conventional techniques of chemistry, it is time consuming and cumbersome, and not readily 
molecular biology, microbiology, recombinant DNA and adaptable to microplate format suitable for high-throughput 
genetics. See, e.g., Maniatis et al. (1982); Sambrook et al. screen. A preferred assay is the phosphate release assay 
(1989); Ausubel et al. (1992); Guthrie and Fink (1991); (such as that used in Piper Phosphate Assay Kit from 
Weissbach and Weissbach (1986); Zaitlin et al. (1985) and 25 Molecular Probes) which offers high sensitivity and extraor- 
Gelvin et al. (1 990). dinary adaptability. The establishment of such an assay 
Method of Use: Drug Susceptibility Assays permits the screening of thousands of compounds, including, 
The bactericidal activity of lead compounds are evaluated but not limited to, D-cycloserine and modified or derivative 
in vitro. Conventional protocols for determination of drug D-cycloserine molecules, for potential inhibitors of D-alanine 
minimum inhibitorv concentration (MIC) mav be used. 30 ligase. 
, , ,  u 
Example ID. employs one example of such assays. For Promising candidate antimycobacterial agents are further 
example, the mycobacterial cells taken from glycerol stock, tested in vitro using M. smegmatis and M. tuberculosis 
or preferably from a single colony, are grown in either reference strains (See Methods of Use: Drug Susceptibility 
M-ADC-TW (for faster growing strains such as M. smeg- Assays). Preferably, the overproducing strains of the present 
matis) or MO-ADC-TW (for slow growing strains such as 35 invention are used at this step to evaluate the potential 
M. avium or M. bovis BCG). Growth is continued in the bactericidal activity of the lead compounds compared with 
absence of test compound until the optical density of 600 nm D-cycloserine. In addition, the susceptibility of the reference 
reaches approximately 0.1 to 1 .O. Medium is supplemented strains to lead compounds indicate the specific pathway or 
with nutrients, if necessary. enzyme targeted. 
Avvroximatelv lo5 CFU in 0.1 ml are inoculated in 40 Method of Use: Analvsis of Drug Action 
. . u 
triplicate onto 96-well microplates containing either serial According to the present invention a method is provided 
twofold dilutions of the test compound or without, for for analyzing the in vivo metabolic change in mycobacteria 
controls. Plates are incubated at 37' C. and checked peri- upon drug treatment. The free amino acid pool is indicative 
odically for growth. MIC is determined as the lowest con- of the pathways which are either shut down or activated by 
centration at which there is no visible growth of bacteria. 45 the test drug. In addition. the alteration of free amino acid 
u 
MIC is confirmed by consistent results from at least three 
independent cultures. 
Alternatively, the bactericidal activity of the test com- 
pound can be evaluated by measuring D-lactate dehydroge- 
nase activity present in the supernatant. D-lactate dehydro- 
genase is a bacterial cytosolic enzyme, and it is only released 
to medium after bacterial lysis. D-lactate dehydrogenase 
detection kits are commercially available and can be adapted 
easily to microplate format. 
Method of Use: Inhibition Assays 
The present invention is based on the evidence, reported 
u 
pool, especially the abundance of L- or D-stereotype of an 
individual amino acid, reflect the mode of action of the drug. 
This method is useful compared with cumbersome bio- 
chemical characterization of various bacterial components, 
50 such as cell wall analysis and lipid analysis. Previously, 
amino acid analysis has been used as a tool to determine the 
composition of purified protein or just simply quantify the 
amino acid level in biological fluids, however its use has not 
previously been reported for analysis of drug action. 
55 Method of Use: Vaccine Development 
The present invention is also useful for the development 
in further detail herein: 1) that Ddl is a binding target of DCS 
and is inhibited in a concentration-dependent manner; 2) that 
Ddl is not significantly affected by DCS at the concentration 
that inhibits Alr; 3) that Alr overproduction contributes to 60 
the maintenance of the internal D-alanine pool, thus antago- 
nizing the inhibition of Ddl by DCS; and 4) that a strain 
overexpressing alr and ddl genes displays increased level of 
resistance to DCS as compared to a strain overexpressing 
only the alr gene. These results, in view of previously 65 
reported results, indicate that Alr is a high-affinity but 
dispensable target of DCS, while Ddl is the low-affinity 
of a novel vaccine against pathogenic mycobacteria, such as, 
but not limited to, M. tuberculosis, M. bovis, M. africanum, 
M. microti, M. leprae, M. avium, M. intracellular, M. 
paratuberculosis, M. ulcerans, M. marinum, and subspecies 
and genetic variants thereof. A mycobacteria can be attenu- 
ated by selection of mutants that are better suited to growth 
in abnormal culture conditions and are therefore less capable 
of growth in the host. The attenuated mycobacterium may 
have inserted therein one or more DNA molecules for 
stimulation of an immune response directed against 
polypepticles encoded by the inserted nucleic acid molecule. 
Vaccines of the present invention may be formulated with provide a attenuation of the mycobacterial strain. Use of a 
conventional carriers andlor adjuvants. promoter that is active in vitro but is inactive, or minimally 
For obvious practical and moral reasons, initial work in active, in vivo will cause lysis of the mycobacterial cells and 
humans to determine the efficacy o experimental composi- release of immunogens which generate an immunological 
tions with regard to such afflictions is infeasible. Accord- 5 response. Replacement of the chromosomal wild type ddl 
ingly, in the early development of any drug or vaccine it is gene with a regulatable ddl gene can be accomplished by 
standard procedure to employ appropriate animal models for means known in the art, including the use of a conventional 
reasons of safety and expense. The success of implementing integrating vector such as those described herein (See 
laboratory animal models is predicted on the understanding Example 1). 
that immunogenic epitopes are frequently active in different 10 The mycobacterial strain used may be a wild-type myco- 
host species. Thus, an immunogenic determinant in one bacterial strain or, alternatively, an alr null mutant myco- 
species, for example a rodent or guinea pig, will generally be bacterial may be used, such as the alr mutant described in 
immunoreactive in a different species such as in humans. Appl'n Ser, NO. U.S. 2003/0133952. 
Only after the appropriate animal models are sufficiently 
developed will clinical trials in humans be carried out to 15 EXAMPLE 1 
further demonstrate the safety and efficacy of a vaccine in 
man. The present invention is further described in the following 
With regard Or pulmonary M. examples, which are offered by way of illustration and are 
tuberculosis, the guinea pig model the 
not intended to limit the invention in any manner, Standard 
human pathology of the disease in many respects. Accord- 20 techniques known in the art or the techniques specifically 
ingly, it is well understood by those skilled in the art that it described below are utilized, 
is appropriate to extrapolate the guinea pig model of this 
disease to humans and other mammals. As with humans, Materials and Methods 
guinea vigs are suscevtible to tubercular infection with low A. Bacterial Strains, Plasmids, and Culture Conditions 
- A - 
doses of the aerosolized human pathogen M. tuberculosis. 25 Bacterial strains and plasmids used in this example are 
Unlike humans where the initial infection is usually con- listed in Table 1. E. coli strains were grown at 37' C. in 
trolled, guinea pigs consistently develop disseminated dis- Luria-Bertani broth or agar. M. smegmatis strains were 
ease upon exposure to the aerosolized pathogen, facilitating grown at 37' C. with shaking (200 rpm; Innova 4300 
subsequent analysis. Further, both guinea pigs and humans incubator shaker; New Brunswick Scientific, Edism, N.J.) in 
display cutaneous delayed-type hypersensitivity reactions 30 Middlebrook 7H9 broth (BBL Microbiology Systems, 
characterized by the development of a dense mononuclear Cockeysville, Md.) supplemented with albumin-dextrose 
cell induration or rigid area at the skin test site. Finally, the complex (ADC) and 0.05% Tween 80 (M-ADC-TW broth). 
characteristic tubercular lesions of humans and guinea pigs For analysis of the intracellular amino acid pools, M. smeg- 
exhibit similar morphology including the presence of Lang- matis was grown in a minimal medium based on the for- 
hans giant cells. As guinea pigs are more susceptible to 35 mulation of Zygmunt (1963) and modified as previously 
initial infection and progression of the disease than humans, described (Chacon et al., 2002). Tryptic soy agar base (Difco 
any protection conferred in experiments using this animal Laboratories, Detroit, Mich.) was used for growth of M. 
model provides a strong indication that the same protective smegmatis on solid media. Transformations of E. coli and M. 
immunity may be generated in man or other less susceptible smegmatis were performed by electroporation with a Gene 
mammals. Those skilled in the art will appreciate that the 40 Pulser (Bio-Rad Laboratories, Richmond, Calif.) as 
present invention may be practiced with various mammalian described previously (Foley-Thomas et al., 1995). The fol- 
hosts including humans and domesticated animals. lowing antibiotics were added to the media when necessary: 
A strain of mycobacteria having a regulatable promoter to kanamycin (Sigma Chemical Co., St. Louis, Mo.) at 50 pg 
control the expression of the ddl gene, whose product is ml-' or carbenicillin (Sigma) at 50 pg ml-' forE. coli strains 
responsible for the synthesis of D-alanyl-D-alanine, will and kanamycin at 10 pg ml-' for M. smegmatis strains. 
TABLE 1 
Strains and plasmids used in this study 
Strain or 
plasmid Description 
Reference 
andlor 
source 
E. coli XL10- 
GOLD 
M. smegmatis 
mc2155 
M. smegmatis 
GPM2 
M. smegmatis 
GPM14 
M. smegmatis 
GPM259 
M. smegmatis 
GPM260 
M. smegmatis 
GPM265 
Tef A(mcrA)183 A (mcrCB-hsdSMR-mrr)l73 endAl 
supE44 thi-1 recAl gyrA96 
relAl lac Hte [F' proAB lacqZ AM15 TnlO (Tef) 
Amy cam7 
High-transformation M. smegmatis mutant derived 
from mc26 
mc2155(p~v262) 
DCS-resistant mutant derived from mc2155; 
overproducing Alr 
mc2155(p~UN250); overproducing Ddl 
GPM14(pBUN250); overproducing both Alr and Ddl 
mc2155(p~UN276); overproducing M. tuberculosis 
Ddl 
Stratagene 
Snapper et 
al., 1990 
Caceres et 
al., 1997 
5 
This work 
This work 
This work 
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TABLE 1 -continued 
Strains and plasmids used in this study 
Strain or 
plasmid Description 
Reference 
andlor 
source 
M. smegmatis 
GPM198A 
pCR2.1 
pMV262 
TA cloning vector 
E. coli-Mycobacterium shuttle plasmid 
pMV262 with a 1.4-kb insert containing the complete 
M. tuberculosis ddl gene 
inserted at the EcoRI site 
Recombinant plasmid isolated from an M. smegmatis 
genomic library which 
hybridized with an internal fragment of the ddl gene 
pMV262 with a 1.4-kb insert containing the complete 
M. smegmatis ddl gene 
inserted at the EcoRI site 
pMV262 with the M. tuberculosis ddl gene inserted at 
the BamHIIHindIII 
site; the M. tuberculosis ddl gene is fused with the 
DNA sequence 
corresponding to the first 6 codons of the M. bovis 
BCG hsp60 gene 
This work 
Invitrogen 
MedImmune, 
Inc.; 
This work 
This work 
This work 
This work 
B. Oligonucleotide primers, nucleic acid manipulations, library construction, chromosomal DNA was partially 
and primer extension analysis. digested with Sau3A1, and fragments of 3.0 to 4.0 kb were 
All oligonucleotide primers were from Integrated DNA purified from 0.8% agarose. This fraction was ligated with 
Technologies, Inc., Coralville, Iowa. For PCR amplification 30 the E. co~i-~ycobacterium shuttle plasmid pMV262 (Con- 
of the complete ddl gene from M. smegmatis were SMD- nell et al., 1993), linearized with BamHI, and dephospho- 
DLCF (5'-CGC ATA AGG CCA GGT CAG3'(SEQ ID rylated. The ligation mixture was transformed into E. coli 
and SMDDLCR (5'-CGA AAA ACC CGT CGT XL10-GOLD (Stratagene, La Jolla, Calif.), and approxi- 
GC-3'(SEQ ID NO:2). The primers for PCR amplification of mately 6,000 recombinants were obtained for a theoretical 
the ddl gene from M. were DDLATBU (5'-GCT 35 representation of p as >99% of the M, smegmatis genome, 
AAG TGC CGA TCG CAA G-3'(SEQ ID NO:3) and 
DDLATBD (5f-ATA ACG CTG CTG CTG GGT C-3f(SEQ A recombinant clone carrying the M. smegmatis ddl gene 
ID NO:4) and TBDDLEXF (5t-CGG GAT CCG TGA GTG was identified from a genomic library by colony hybridiza- 
CTA ACG AC3t(SEQ ~ 0 ~ 5 )  and TBDDLEXR (5t-CGG tion using a species-specific probe. An internal fragment of 
AAG CTT GTG CCG ATC GCA AGC-~~(SEQ ID ~ 0 ~ 6 ) .  40 the M. smegmatis ddl gene was amplified by PCR using a 
~h~ primers SMDDLPE (51-AAA CGC TCC GGA TCG pair of degenerate primers, DDLF and DDLR, based on two 
AGG TTG3'(SEQ ID NO:7) and TBDDLpE (5I-GAG ATG signature peptides of bacterial Ddl enzymes (Dutka-Malen 
GCG TGC TCG TTG-3'(SEQ ID NO:8) were used in primer et al., 1992). This amplified fragment was verified and 
extension analysis for the ddl mRNA of M. smegmatis and radiolabeled with the Rediprime I1 labeling system (Amer- 
M. tuberculosis, respectively. PCR amplifications were per- 45 sham Pharmacia Biotech, Piscataway, N.J.). For screening 
formed in a Perkin-Elmer GeneAmp 9600 thermal cycler the library, about 10,000 colonies from the library pool were 
(Roche Molecular Systems, Branchburg, N.J.) by using the plated, transferred to the NYTRAN nylon membrane (Mid- 
Expand high-fidelity PCR system (Roche hfolecular Bio- west Scientific, Valley Park, Mo.), and screened with the 
chemicals, Indianapolis, Ind.). For restriction digestions, labeled probe as described previously (sambrook et al,, 
ligations, and agarose gel electrophoresis, standard Proce- 50 1989). After three rounds of screening, the recombinant 
dures previously described (SambrOOk et al., 1989) were plasmid pBUN172 was identified and to contain 
followed. Total RNAfrom M. smegmatis strains was isolated the full-length ddl gene, This sequence is identical to the 
using RNAWIZ (AmbiOn, Inc., Austin, Tex.) with 
sequence at GenBa& with accession no, AF077728 (Be- 
modifications (Bashyam and Tyagi, 1994). Primer extension langer et al., 2000) and the sequence from the unfinished M. 
analysis of the ddl mRNA was carried out as described 55 
previously (Davis et al,, 1994). The oligonucleotide was ""'egmatix mc2c'155 genome [(J. Craig Center 1nstitute)l. 
radiolabeled with [ y - 3 2 ~ ] ~ ~ ~  by using T4 polynucleotide D. Drug Susceptibility Assays. 
kinase (Promega, Madison, Wis.), and the reactions were MICs were determined by a microdilution method 
extended with Moloney murine leukemia virus reverse tran- described previously (Takiff et al., 1996) with minor modi- 
scriptase (Promega). Radioactivity in primer extension prod- 60 fications. Briefly, M. smegmatis cells were grown in 
ucts was quantified with a Phosphorlmager by using M-ADC-TW to mid-exponential phase (optical density at 
ImageQuant, version 3.3 (Molecular Dynamics, Sunnyvale, 600 nm, 0.6 to 1.0). Approximately lo5 CFU in 0.1 ml were 
Calif.). inoculated in triplicate onto 96-well microplates containing 
C. M. smegmatis genomic library construction and clon- serial twofold dilutions of inhibitory compounds. Plates 
ing of the M. smegmatis ddl gene. 65 were incubated at 37' C. and examined daily. The MIC was 
Chromosomal DNA from M. smegmatis mc21 55 was defined as the minimal concentration of the drug or inhibitor 
prepared as described previously (Whipple et al., 1987). For that prevented visible bacterial growth after 48 h. Each MIC 
US 7,371,571 B2 
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represents the consistent result from at least three indepen- The lysate was centrifuged at 4' C. for 30 min at 30,000xg 
dent cultures. Amikacin, DCS, OCDA, ethambutol, and to remove bacterial debris. Protein was removed from the 
vancomycin (all from Sigma) were prepared in sterile deion- supernatant by serial passages through YM-10 and YM-3 
ized water. Rifabutin (Amersham Pharmacia) was prepared Centricon concentrators (Millipore Corp., Bedford, Mass.). 
in dimethyl sulfoxide (Fisher Scientific, St. Louis, Mo.). All 5 Determination of the abundance of individual amino acids 
further dilutions of each antibiotic were prepared in growth was performed at the Amino Acid Geochronology Labora- 
medium. Inhibition of colony formation by DCS was evalu- tory of Northern Arizona University (Flagstaff, Ariz.) by a 
ated as described previously in Caceres et al., (1 997), which reverse-phase high-performance liquid chromatography 
is incorporated herein by reference. Appropriate dilutions of (HPLC) procedure described previously (Kaufman and 
exponentially growing M. smegmatis cells were plated onto 10 Manley, 1998). This procedure is able to detect nine pairs of 
agar containing 0 to 1,200 pg of DCS ml-l. Colonies were L- and D-amino acids in the subpicomole range. For each 
counted after 5 days of incubation at 37' C. Statistical sample, the area of the peak representing L-glutamate con- 
analysis was conducted using the SAS general linear model stituted 50 to 60% of the total area. Thus, the abundance of 
procedure (SAS Institute, Cary, N.C.). each amino acid was calculated as the area under the 
E. Preparation of Crude Cell Extracts from M. smegmatis 15 corresponding peak and expressed relative to this pool. 
Strains. H. Overproduction and Purification of M. tuberculosis 
M. smegmatis cells were harvested at exponential phase Ddl 
and concentrated 50-fold in ice-cold 50 m~ T ~ ~ ~ - H c ~  ( p  Introduction. The development of assays to screen for and 
8.0). cells were disrupted with a ~~~~~h cell characterize novel inhibitors of the M. tuberculosis Ddl 
(Them0 Spectronic US, Rochester, N.Y.) at 14,000 lb/in2. 20 emyme requires large amounts Of purified protein. 
~h~ lysate was centrifuged at 40 C, for 30 min at 30,000xg a preliminary biochemical characterization of inhibitors 
to remove cell debris, ~h~ was subjected to could be undertaken with crude cell extracts from M. tuber- 
ultracentrifugation at 40 C, for 4 h at 1 1 0 , 0 0 0 ~ ~  to remove culosis, a more thorough analysis of biochemical parameters 
the membrane fraction. The recovered supernatant was require purified products. Furthermore, large amounts Of the 
dialyzed twice against 50 m~ T ~ ~ ~ - H c ~  ( p ~8.0) at 40 C, and 25 purified protein are required for crystallographic studies. 
sterilized by filtration through 0.22-pm-poresize filters. The One P ~ ~ ~ ~ ~ ~ ~ ~ ~ Y  is to purify the protein from M. 
protein concentration was determined by using the DC tuberculosis cell extracts. However, the purification yield is 
protein assay (Bio-Rad) as recommended by the manufac- low, necessitating large cultures of a serious human patho- 
turer. gen. Fortunately, recombinant DNA technology provides the 
30 means to produce large amount of recombinant products F. Enzyme Assays. 
using hosts such as Escherichia coli, which are safe to 
The crude extract was assayed for Ddl activity by a handle, and easy to grow and manipulate genetically. In 
modified thin-la~er (TLC)-based method general, the E, coli system is able to synthesize the proper described previously and Wright, 1998). This 
mycobacterial protein; however, this is confirmed for the 
procedure can quantitatively determine the amount Of D-ala- 35 protein of interest, The M, tuberculosis Ddl in E, coli is 
d i ~ e ~ t i d e .  crude extracts (5 to 30 pg designated herein as r-Ddl, The corresponding biochemical 
Of protein) were incubated at 370 C. for in a 5 0 - ~ 1  properties of the native M, tuberculosis Ddl are compared 
'Ontaining 50 mM Tris-HC1 (pH 7.8), l o  mM 
with those of i--Ddl, The purify proteins are used to deter- 
MgC12, 10 mM KCl, 50 mM unlabeled o-alanine, 6 mM 
mine basic biochemical parameters including the inhibitory 
2'5 mM glutathione> and 5'0 pCi Of [1-14ClD-a1anine 40 for the well-known inhibitor DCS and deriva- (100 pCi/ml; ICN Biochemicals, Inc., Costa Mesa, Calif.). tives thereof, 
For inhibition assays, DCS was added to the final concen- Likewise, the determination of biochemical 
trations Of 50, loo, 200, 400, and pg ml-l. are performed as a means to compare the properties of r-Ddl 
10 p1 of the reaction mixture was applied to cellulose-backed and the native as well as to the values TLC plates (Sigma), and ascending 
was 45 obtained in our study with those previously reported in developed in n-butanol-acetic acid-water (12:3:5) until the classic studies of mycobacteria (David et al,, 1969) and 
solvent reached the top of the TLC plate. The plate was dried other microbial systems, 
at 100" C. for 5 min, and the radioactivity corresponding to Experimental design, The M, tuberculosis ddl gene is 
the position of the D-alanine and D-alanine: D-alanine dipep- subcloned into an E, coli overexpression vector, so that a 
tide was measured with a Phos~horlmager' pecific 50 polyhistidine-tagged Ddl protein is synthesized by the E, 
was calculated as micromoles of D-alanine consumed per 
coli recombinant clone, The fusion protein is purified from per minute. The racemase activity was E, coli Ddl and other endogenous components by one-step 
measured in the direction of the conversion of L-alanine to chromatography based on the properties of the 
o-alanine by a coupled s~ectro~hotometric method (Wijs- histidine tag. ~ ~ l l ~ ~ i ~ ~  removal of polyhistidine, poly- 
man, 1972) with modifications ('hacon et 2002). 'pe- 55 clonal antibodies are raised against the r-Ddl and used to 
cific activity was calculated as described previously (Cac- purify the native M, tuberculosis Ddl from semi-purified 
eres et al., 1997). extracts. Using biochemical assays, the kinetic parameters of 
G. Analysis of Intracellular Pools of Amino Acids. V,,,, K, for D-alanine, and K, for DCS for both r-Ddl and 
M. smegmatis cells were grown in minimal medium until native Ddl, are measured. 
exponential phase and split into two subcultures, and DCS 60 To obtain large amount of M. tuberculosis Ddl enzyme, 
was added to a final concentration of 75 pg ml-l to one of the ddl gene is PCR amplified based on the genome 
the subcultures. After 2 h of incubation, cells were harvested sequence and cloned into an E. coli expression vector to 
at 4" C. by centrifugation, washed twice with ice-cold achieve a high level of expression. Preferably, the commer- 
double-distilled water, and concentrated 50-fold. Cells were cially available PET system (Novagen) is used. The advan- 
sonicated in a salt-ice-water bath with a Vibra-Cell model 65 tage of this system is that the inserted gene will be under the 
VC600 sonicator (Sonic and Materials, Inc., Danbury, control of the strong T7 promoter, allowing large quantities 
Conn.) for 10 min at 80% power output and 50% duty cycle. of protein to be produced. In the PET system, the T7 RNA 
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polymerase gene BL21 (DE3), and is itself under the control except for the last affinity chromatography step. Altema- 
of the lac promoter. In the presence of the inducer IPTG, T7 tively, the crude cell-free extract will be concentrated and 
RNA polymerase is expressed and will initiate transcription loaded on the affinity chromatography column, without 
of the ddl gene located in the plasmid. The M. tuberculosis additional purification steps. 
ddl gene is expressed as a fusion protein with a poly-His tag 5 Determination of kinetic parameters. Using both the TLC 
at either the N- or C-terminus, for use in purification of the and the P, release assay, the type of inhibition and the 
resulting protein by a single-step affinity chromatography. corresponding kinetic parameters are determined. The V,,,, 
After optimization of protein expression, a large-scale K, and K, for DCS will be evaluated by the double recip- 
experiment is performed to obtain milligram levels of puri- rocal plot method. Preferably, the Pi assay is used because 
fied protein. The purity and identity of the recombinant Ddl l o  it is readily adaptable to a high throughput screen procedure. 
protein is verified by two-dimensional SDS-PAGE, mass 
spectroscopy and N-terminal sequencing, based on the EXAMPLE 2 
deduced protein sequence and computer-predicted charac- 
teristics, including molecular weight and isoelectric point. Overexpression of the M. smegmatis and M. 
Primers for the M. tuberculosis ddl gene are designed so 15 tuberculosis ddl Genes in Recombinant M. 
that the 5' ends contain the proper restriction enzyme sites to smegmatis. 
facilitate cloning. These restriction sites will be chosen using 
the following criteria: the sites are not present in the ddl The M. smegmatis ddl gene was isolated from a genomic 
gene; and they will produce an in-frame fusion with the His library as described in Example 1. The DNA fragment 
tag in the vector after cloning. Thermostable high-fidelity 20 containing the ddl gene coding sequence, including 190 bp 
DNA polymerase is used to amplify the ddl gene from M. of the 5' flanking region and 35 bp of the 3' flanking region, 
tuberculosis genomic DNA. The resulting PCR produce is was amplified by PCR and ligated into the EcoRI site of 
then digested with the appropriate restriction enzymes and pMV262 to generate pBUN250. This plasmid was elec- 
cloned into PET 15b following standard cloning procedures. troporated into M. smegmatis mc2155, yielding GPM259. 
Restriction digestion analysis and DNA sequencing of the 25 Since pMV262 is present in M. smegmatis at 5 to 10 copies 
insertional junctions is performed to ensure the correct (Caceres et al., 1997), the ddl gene is expected to be 
in-frame fusion. After verification, the plasmid is trans- overexpressed in the recombinant M. smegmatis strain due 
formed into E. coli BL21 (DE3), which carries the T7 RNA to a gene dosage effect. This was confirmed by primer 
polymerase gene under the control of the lac promoter. extension analysis using total RNA isolated from mc2155 
Protein expression is induced by adding 1 mM IPTG to 30 and GPM259. Radiometric quantitation of the primer exten- 
cultures of recombinant E. coli when the OD600 is between sion bands confirmed that GPM259 overproduced the ddl 
0.5 and 1.0. Cells are harvested at various time points after transcript by 25-fold compared to mc2155. In both samples, 
induction and whole-cell crude extracts are analyzed by two transcriptional start sites were detected, one immedi- 
SDS-PAGE to detect the expression of the Ddl protein. ately upstream and another 3 nucleotides upstream of the 
Optimal conditions for protein production are obtained from 35 start codon (GTG) (FIG. 1A). Further analysis of the 
small-scale analysis of variations in initial culture density, sequence immediately adjacent to the start codon did not 
inducer concentration, growth temperature, agitation speed reveal any significant RNA secondary structures, excluding 
and cell density at harvest. Optimized conditions are the possibility that the two bands detected were the result of 
adopted for large-scale preparation. Cells are lysed by premature extension products. It has been found for the 
French Press and the resulting cell lysate passed through a 40 Mycobacterium fortuitum blaF (Timm et al., 1994) and 11 
Ni affinity column. Recombinant protein with the His tag streptomycete genes (Strohl, 1992) that transcription start 
bound to the column is eluted and the process repeated until sites are extremely close to the start codon. This may suggest 
the protein is purified close to homogeneity. The His tag in that translation initiation in both mycobacteria and strepto- 
the recombinant protein is cleaved by thrombin prior to mycetes has less-stringent requirements for the recognition 
analysis. The purity and identity of the recombinant protein 45 of a ribosome-binding site. 
is confirmed by 2-D SDS-PAGE, mass spectrometry and Following the same strategy, we constructed an M. smeg- 
N-terminal sequencing. matis recombinant strain, GPM19XA, carrying the plasmid 
Purification of M. tuberculosis native Ddl protein. The pBUN12XA, a pMV262-based plasmid containing the M. 
Ddl from E. coli and M. tuberculosis is purified to determine tuberculosis ddl gene coding sequence, including 140 bp of 
the identity of the recombinant and native proteins. Given 50 the 5' flanking region and 130 bp of the 3' flanking region. 
the cytoplasmic localization of the Ddl enzyme, we plan to Total RNA isolated from GPMl9XA was subjected to primer 
prepare crude cell extracts of M. tuberculosis H37Rv are extension analysis using oligonucleotides specific to either 
prepared and the cytosolic fractions are separated as the M. smegmatis or the M. tuberculosis ddl gene. The 
described above for M. smegmatis. If necessary, further results revealed that this strain overexpressed the endog- 
partial purification of this crude cell extract is performed by 55 enous M. smegmatis ddl gene rather than the plasmid-carried 
treating the cytosolic fraction with 0.3 mg of RNase and 0.3 M. tuberculosis ddl gene. To circumvent this problem, a 
mg of DNase, followed by centrifugation at 100,000xg for different strategy was followed. Briefly, the M. tuberculosis 
2 h at 4" C. in a Beckman Ultracentrifuge by using a Ti 40 ddl gene was amplified by PCR and cloned into pMV262, 
rotor. To the precooled new supematant fraction, distilled yielding pBUN276. In this construct, the M. tuberculosis ddl 
acetone is added to precipitate the lipopolyssacharide-like 60 gene is fused in frame with the first six codons of the 
components. The supernatant of the acetone precipitation is Mycobacterium bovis BCG hsp60 gene and is under the 
centrifuged a 100,000xg for one hour to precipitate proteins. control of its promoter. Total RNA isolated from the corre- 
The pellet is redissolved in buffer, and the Ddl protein is sponding recombinant strain, GPM265, was subjected to 
further purified by affinity chromatography using the poly- primer extension analysis as described above. In this case, 
clonal antibodies raised against the purified r-Ddl. Most of 65 the chromosomally encoded ddl gene in GPM265 was 
these steps are similar to those described in the classic expressed at a level similar to the level in wild-type mc2155 
studies of the M. tuberculosis Ddl by David et al. (1969), (FIG. lA), while the episomal M. tuberculosis ddl gene was 
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expressed at an approximately 30-fold-higher level than the DCS for mc2155, GPM259, GPM265, and GPM14 were 
chromosomally encoded ddl gene (FIG. 1B). The transcrip- determined (Table 2). GPM14, overproducing Alr, is a 
tional start site of the M. tuberculosis ddl gene located on spontaneous DCS-resistant mutant derived from mc2155 
pBUN276 was identified as the G nucleotide located 183 bp (Caceres et al., 1997). The MICs of DCS for strains 
upstream of the start codon of the hsp60 gene, consistent 5 GPM259 and GPM265 (both at 150 pg ml-l) were twofold 
with previous observations (Stover et al., 1991). As greater than that for mc2155 (75 pg ml-l) but were lower 
expected, no M. tuberculosis ddl transcript was detected than that for GPM14 (300 pg ml-l). Thus, recombinant 
from mc2155 or GPM259 total RNA. strains overproducing Ddl showed increased levels of resis- 
tance to DCS but were not as resistant as the Alr-overpro- 
EXAMPLE 3 l o  ducing strain GPM14. The susceptibilities of these strains to 
13CDA, which interferes with the incorporation of D-alanine 
Enzymatic Characterization of M. smegmatis into the bacterial cell wall, were also determined (Table 2). 
Strains BCDA, an analog of D-alanine, was reported to target 
bacterial alanine racemases and transaminases (Manning et 
The overexpression of the M. smegmatis or M. tubercu- 1s al., 1974) and showed a synergistic effect with DCS against 
losis ddl gene was further confirmed by measuring Ddl M. tuberculosis (David, 2001). In this study, only the strain 
enzyme activities. For this, Ddl-specific activities in cell overproducing Alr showed increased resistance to BCDA, as 
crude extracts from mc2155, GPM259, and GPM265 were the MIC for GPM14, 100 pg ml-l, is fourfold higher than 
determined by the TLC-based method described in Example those for other strains with wild-type levels of Alr. These 
1. A typical autoradiogram of the TLC-based Ddl enzyme 20 data are consistent with the mode of action of OCDA, which 
assays for strain GPM259 is shown in FIG. 2A. Ddl-specific inhibits the Alr enzyme. In addition, susceptibilities to other 
activities in crude extracts from GPM259 and GPM265 were antimicrobial agents targeting cell wall biosynthesis (etham- 
about 35 and 30 times greater, respectively, than that in butol and vancomycin), RNA synthesis (rifabutin, a struc- 
mc21 55 extracts (FIG. 3A). These increases in Ddl activity tural analog of rifampin with higher antimycobacterial activ- 
were consistent with the primer extension results. As a 25 ity), and protein synthesis (amikacin) of these M. smegmatis 
control, Alr enzyme activities were concurrently determined strains were identical. The DCS resistance phenotype of the 
by a coupled spectrophotometric method as described in Ddl-overproducing strains was further confirmed by plating 
Materials and Methods. As expected, cell crude extracts bacteria on solid agar containing various concentrations of 
from mc2155, GPM259, and GPM265 displayed similar Alr DCS. Consistent with the MIC data, GPM259 and GPM265 
activities (FIG. 3B), indicating that overexpression of the 30 are more resistant to DCS than the wild-type mc21 55 but less 
ddl gene is specific and does not alter the expression of the resistant than the Alr-overproducing strain GPM14 (FIG. 5). 
alr gene. Furthermore, there were no observed differences Furthermore, this type of intermediate level of resistance to 
between the recombinant strains overproducing Ddl and the DCS is not related to Alr, since crude extracts from both 
wild-type strain regarding growth rate, growth saturation GPM259 and GPM265 contained a wild-type level of Alr 
density, and colony morphology, indicating that the overex- 35 activity (FIG. 3B). Therefore, overproduction of the Ddl 
pression of the ddl gene is not toxic to the host. enzymes leads to a DCS resistance phenotype in M. smeg- 
Previously, David et al. (1969) reported that DCS com- matis. However, this level of resistance may not suffice for 
petitively inhibits the M. tuberculosis Ddl enzyme. In this selection of DCS-resistant clones by following the strategy 
study, we performed in vitro inhibition assays to determine described above. 
the Ddl-specific activities of crude extracts from mc2155, 40 
GPM259, and GPM265 in the presence of increasing con- EXAMPLE 5 
centrations of DCS. A typical autoradiogram of the inhibi- 
tion assay for the crude extract of GPM259 is shown in FIG. Construction and Characterization of an 
2B. The degree of inhibition for the Ddl activities in these Alr-Ddl-overproducing Mycobacterial Strain 
extracts increased proportionally to the DCS concentration 45 
(FIG. 4). No statistically significant differences between the It has been reported previously that a specific type of 
extracts from mc2155 and GPM259 were observed. How- DCS-resistant Streptococcus gordonii mutants displayed 
ever, though the inhibition of the Ddl activity in GPM265 elevated Alr and Ddl activities and that the level of resis- 
crude extract followed a similar pattern, the percentage of tance to DCS is higher than that for mutants with elevated 
inhibition was approximately 10% higher at each concen- 50 Alr activity only (Reitz et al., 1967). To test the effect of the 
tration of DCS (Pe0.02). Since the primer extension analysis overproduction of both Alr and Ddl in M. smegmatis on DCS 
indicated that more than 95% of the Ddl activity present in susceptibility, we introduced the multicopy plasmid 
the crude extract of GPM265 is from the expression of the pBUN250 carrying the ddl gene into the Alr-overproducing 
M. tuberculosis ddl gene, this slight difference may reflect a strain GPM14. As expected, the resulting strain, GPM260, 
moderately higher sensitivity of the M. tuberculosis Ddl 55 overproduced both Alr and Ddl as demonstrated by enzy- 
enzyme to DCS inhibition. In summary, these data indicate matic characterization (FIG. 3). In addition, the degree of 
that both M. smegmatis and M. tuberculosis Ddl enzymes are inhibition of the Ddl activities in extracts from GPM260 and 
inhibited by DCS in a concentration-dependent manner and its parental strain, GPM14, increased proportionally to the 
provide further evidence that Ddl is a target of this drug. DCS concentration (FIG. 4). No statistically significant 
60 differences between these extracts were observed (P>0.28). 
EXAMPLE 4 Note that the overproduction of Alr in GPM14 and GPM260 
does not alter the degree of in vitro inhibition of the Ddl 
Drug Susceptibilities of M. smegmatis Strains enzyme by DCS. Thus, increasing amounts of Alr protein do 
not seem to affect the inhibitory effect of DCS on Ddl 
To test whether Ddl overproduction confers a DCS resis- 65 activity. The susceptibilities of GPM260 to OCDA, etham- 
tance phenotype, we evaluated the susceptibilities of M. butol, vancomycin, rifabutin, and amikacin were identical to 
smegmatis strains overproducing Ddl to DCS. The MICs of those of the parent strain, GPM14 (Table 2). However, 
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GPM260, overproducing both Alr and Ddl, was significantly D-alanine. The observed decrease of the D-alanine pool is 
more resistant to DCS than the wild-type strain or strains statistically significant for strains GPM259 (P=0.05), 
overproducing only Alr or Ddl (Table 2 and FIG. 5). GPM14 (P=0.01), and GPM260 (PP0.01). For strain 
mc2155, the decrease of the D-alanine pool fell below the 
TABLE 2 5 statistically significant level (P>O.ll). However, this strain 
displayed the maximum accumulation of L-alanine, and the 
MICS of DCS M. smermatis strains L-alanine-to-D-alanine molar ratio increased 3.5-fold 
MIC" (p~o.01). 
Phenotype (WE ml-1) The intracellular pools of D- and L-alanine were also 
l o  dependent on the steady-state production levels of Alr and 
Strain Alr Ddl fiCDA" Ddl enzymes. In cells not exposed to DCS, a twofold excess 
mc2155 wtC wt 25.0 75.0 of the L-stereoisomer was observed for strains mc2155, 
GPM2 wt wt 25.0 75.0 GMP259, and GPM 260 (PP0.30) but strain GPM14 dis- 
GPM259 wt Overproduced 25.0 150 played almost equimolar amounts of both isomers, a result 
GPM14 Overproduced wt 
GPM260 Overproduced Overproduced 36:: 15 significantly different from those for the rest of the strains 
GPM265 wt Overproducedd 25.0 150 (Pe0.01). These data suggest that the overproduction of Alr 
favors the maintenance of a relatively abundant pool of 
"MICs were determined in M-ADC-TW media by a microdilution method D-alanine, ~ ~ ~ ~ t ~ ~ ~ t  with DCS led to the most significant 
as described in Materials and Methods. 
"A chi-square test was performed for MICs obtained from at least four changes, as observed by comparing effects among different 
independent cultures. Susceptibilities to fiCDA can be divided into two 20 strains. In the wild-type strain mc2155, an eightfold excess 
groups (group I, 1112155, GPM2, GPM259, and GPM265; group 11, of L- over D-alanine was observed. In the Alr-overproducing 
GPM14 and GPM260). Significant differences (P < 0.001) between these Strain GPM14, only a three-fold excess was observed, 
two groups were detected, while no significant differences (P 2 0.537) 
within each group were detected. representing a statistically significant difference from the 
'A chi-square test was performed for MICs obtained from at least seven wild-type strain (Pe0.02). In contrast, the Ddl-overproduc- 
independent cultures. Susceptibilities to DCS can be divided into four 25 ing strains ~ ~ ~ 2 5 9  and ~ ~ ~ 2 6 0  displayed an 18- to 
groups (group I, 1112155 and GPM2; group 11, GPM259 and GPM265; 
group 111, GPM14; IV, GPM260), Significant differences between 20-fold excess of L-alanine. This result indicated that there 
these two groups were detected (group I versus group 11, P = 0.001; group were no significant differences between GPM259 and 
11 versus group 111, P P = 0.001; group IIIversus group VI, P = 0.008), GPM260 (P>O.XO) but that these two strains differed sig- 
while no significant differences within each group were detected (group I, nificantly from both the wild-type strain ( ~ ~ 0 . 0 4 )  and 
P = 0.881; group 11, P = 0.893). 
d ~ o r e  than 95% of the Ddl activity in GPM265 is due to the expression 30 GPM14 (PPO.O1). these changes are 
of the episomal copy of the M. tuberculosis ddl gene (see text). determined by a significant reduction in the D-alanine pool 
"wt, wild type. compared to the values for the wild-type strain mc2155 
(PP0.03) and GPM14 (PP0.01). These observations suggest 
EXAMPLE 6 that, in the Ddl-overproducing strains GPM259 and 
35 GPM260, Ddl is not significantly inhibited by DCS at 
Analysis of the Intracellular L- and D-alanine Pools concentrations that inhibit Alr. Moreover, the inhibition of 
Alr by DCS was quite effective, since the Alr-Ddl-overpro- 
The incorporation of D-alanine into peptidoglycan ducing strain GPM260 displayed values for both the D- and 
requires the sequential interconversion of L- into D-alanine L-alanine pools similar to those displayed by strain 
followed by the formation of the D-alanine dipeptide, reac- 40 GPM259, with wild-type Alr levels and overexpression of 
tions catalyzed by Alr and Ddl, respectively. The interplay DdL. 
between D-alanine biosynthesis by Alr and its consumption 
by Ddl contributes to the determination of the intracellular EXAMPLE 7 
level of this amino acid. Inhibition of Alr alone would High Throughput Screening of Potential Ddl decrease the intracellular pool of D-alanine. Therefore, in 45 
live bacilli exposed to sublethal concentrations of DCS (near Inhibitors 
the MIC for the wild-type strain), if Alr is inhibited to a D-alanine ligase (Ddl) activity is determined in a cell-free greater extent than Ddl, a decrease in the D-alanine pool phosphate release assay (Piper Phosphate Assay Kit, 
would be expected. To test this hypothesis, we determined Molecular Probes). This assay measures the amount of the intracellular alanine pools of mc2155, GPM14' 50 inorganic phosphate generated during the production of GPM259, and GPM260 with and without DCS treatment D-alanyl-D-alanine, Purified M, tuberculosis Ddl enzyme 
a reverse-phase HPLC. This methodology allowed detection (Example 1H.) is used in the assay to reduce background and 
of D- and L-alanine, L-arginine, L-asparaginelaspartate, D- increase sensitivity of the assay. The assay is performed 
and L-glutaminelglutamate (Glx), glycine, L-isoleucine, 
according to manufacturers instructions. L-leucine, D-phenylalanine, L-serine, and D- and L-valine 55 Promising lead drug candidates are further tested in vitro from samples prepared from cell extracts as described in 
using reference mycobacterial strains, such as M. smegmatis Example 1 (FIG. 6). It was observed that the L-Glx pool was 
and M. tuberculosis Ddl overproducing strains, GPM259, the most abundant, probably reflecting its crucial role in GPM260, and GPM265, to evaluate the potential mycobac- 
nitrogen metabolism. Moreover, this pool displayed no tericidal activity of the lead compounds compared to DCS. 
significant variations upon DCS treatment (P>0.63), so it 60 
was used as a standard to normalize all other intracellular EXAMPLE 8 
pools. 
Comparison of the amino acid pools in each strain upon Construction of Live-attenuated Vaccine Against 
DCS exposure revealed that this treatment had a specific Mycobacterium tuberculosis 
effect on the intracellular alanine pools (FIG. 7). In all 65 
strains tested, DCS treatment led to a significant accumula- Vaccine development starts with virulent M. tuberculosis 
tion of L-alanine (Pe0.03) and a concomitant decrease of microorganisms from which attenuated mutants are gener- 
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ated. These mutants preferably carry at least two attenuating Belanger and Inamine, 2000. Genetics of cell wall bio- 
deletion mutations and no antibiotic resistant markers, so as synthesis, p. 191-202. In G. F. Hatfull and W. R. J. Jacobs 
to avoid unwanted reversions or transfers of drug-resistance. (ed.), Molecular genetics of mycobacteria. ASM Press, 
Vaccine strains may include one or more additional muta- Washington, D.C. 
tions. The vaccine strain is optionally potentiated by co- 5 Belanger, et al., 2000. Genetic analysis of peptidoglycan 
administration of cytokines or by endowing the engineered biosynthesis in mycobacteria: characterization of a ddlA 
strain with the capability to produce cytokines or phagosome mutant of Mycobacterium smegmatis. J. Bacteriol. 182: 
membrane disrupters, such as lysteriolysin. Preferably, tem- 6854-6856. 
poral expression of these genes is regulated by promoters Brennan and Nikaido, 1995. The envelope of mycobac- 
solely active inside phagocytic cells. l o  teria. Annu. Rev. Biochem. 64:29-63. 
A strain of M. tuberculosis is constructed which is Caceres et al., 1997. Overexpression of the D-alanine 
merodiploid, with an episomal copy of the ddl gene under racemase gene confers resistance to D-cycloserine in Myco- 
the control of a promoter that is not expressed in vivo. The bacterium smegmatis. J. Bacteriol. 179:5046-5055. 
chromosomal copy of the native ddl gene is inactivated by Chacon et al., 2002. Mycobacterium smegmatis D-alanine 
means known in the art, such as point mutation or by 15 racemase mutants are not dependent on D-alanine for 
addition, deletion, or substitution of one or more base pairs, growth. Antimicrob. Agents Chemother. 46:47-54. 
preferably by deletion of one or more base pairs. The Connell et al., 1993. Effective immunization against cuta- 
resulting strain is able to grow in synthetic medium but is neous leishmaniasis with recombinant bacille Calmette- 
unable to grow in viva, because ~-alanyl-~-alanine is not Guerin expressing the Leishmania surface proteinase gp63. 
synthesized. As a result the cells undergo spontaneous lysis, 20 Proc. Natl. Acad. Sci. USA90: 11473-11477. 
releasing immunodominant B and T cell antigens. The strain David, 1971. Resistance to D-cycloserine in the tubercle 
may further include inactivation of the air gene and/or may bacilli: mutation rate and transport of alanine in parental 
include genes for recombinant foreign antigens. cells and drug-resistant mutants. Appl. Microbiol. 21:888- 
Such strains would be useful for the generation of attenu- 892. 
ated live-attenuated vaccine candidates against tuberculosis 25 David et al., 1969. Susceptibility of mycobacterial D-ala- 
and other human or animal diseases caused by mycobacteria nyl-D-alanine synthetase to D-cycloserine. Am. Rev. Respir. 
such as leprosy, Johne's disease, and possibly Crohn's Dis. 100:579-581. 
disease. Because such strains are impaired in the ability to David, 2001. Synergic activity of D-c~closerine and ss- 
synthesize the basic building block of cell walls, peptidogly- chloro-D-alanine against Mycobacterium tuberculosis. J. 
can, the strains undergo spontaneous lysis in vivo. Lysis 30 Antimicrob. Chemother. 471203-206, 
provides improved antigen delivery and containment of the Davis et al., 1994. Basic methods in molecular biology, 
vaccine strain. 2nd ed. Appleton & Lange, Nonvalk, Conn. 
Dutka-Malen et al., 1992. Sequence of the vanc gene of 
DEPOSIT INFORMATION Enterococcus gallinarum BM4174 encoding a D-alanine: 
35 D-alanine ligase-related protein necessary for vancomycin 
The plasmid pBUN276 has been deposited with the resistance. Gene 112:53-58. 
American Type Culture Collection (ATCC), 10801 Univer- Farmer, 2001. and DOTS-plus: not the 
sity Boulevard, Manassas, Va. 20110-2209, USA, on Jan. answer. Ann. N. Y. Sci. 953:165-184. 
26, 2007 in accordance with the ~~d~~~~~ T~~~~ and have Foley-Thomas et al., 1995. Phage infection, transfection 
been accorded accession number PTA-8190. 40 and transformation of Mycobacterium avium complex and 
From the foregoing it will be seen that this invention is Mycobacterium paratuberculosis. Microbiology 141:1173- 
one well adapted to attain all ends and objectives herein- 1181. 
above set forth, together with the other advantages which are et (eds) 990. 
obvious and which are inherent to the invention. Manual. Kluwer Academic Press, Dordrecht, Netherlands. 
Since many possible embodiments may be made of the 45 Guthrie and Fink, 1991. Guide to Yeast Genetics and Molecular Biology (Academic Press). invention without departing from the scope thereof, is to be Kaufinan and Manley, 1998. A new procedure for deter- 
understood that all matters herein set forth or shown in the 
mining enantiomeric (DIL) amino acid ratios in fossils using 
accompanying drawings are to be interpreted as illustrative, 
reverse phase liquid chromatography. Quat. Sci. Rev. 
and not in a limiting sense. 
50 171987-1000. 
'pecific embodiments have been shown and dis- Lambe* and Neuhaus, 1972, Mechanism of D-cycloserine 
cussed, various modifications may of course be made, and action: alanine racemase from Escherichia coli W, J, Bat- 
the invention is not limited to the specific forms or arrange- teriol, 110:978-987, 
ment of parts and steps described herein, except insofar as Maniatis et al,, 1982, Molecular Cloning: A Laboratory 
such limitations are included in the following claims. Fur- 55 Manual (Cold Spring Harbor Laboratory, Cold Spring Har- 
ther, it will be understood that certain features and sub- bor, N,Y,), 
combinations are of utility and may be employed without Manning et al,, 1974, Inhibition of bacterial growth by 
reference to other features and sub-combinations. This is beta-chloro-D-alanine, Proc, Natl, Acad, Sci, USA 71:417- 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 8 
<210> SEQ ID NO 1 
<211> LENGTH: 18 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<220> FEATURE : 
<223> OTHER INFORMATION: SMDDLCF PRIMER 
<400> SEQUENCE: 1 
cgcataaggc caggtcag 
<210> SEQ ID NO 2 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<220> FEATURE : 
<223> OTHER INFORMATION: SMDDLCR PRIMER 
<400> SEQUENCE: 2 
cgaaaaaccc gtcgtgc 
<210> SEQ ID NO 3 
<211> LENGTH: 19 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<220> FEATURE : 
<223> OTHER INFORMATION: DDLATBU PRIMER 
<400> SEQUENCE: 3 
gctaagtgcc gatcgcaag 
<210> SEQ ID NO 4 
<211> LENGTH: 19 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: DDLATBD PRIMER 
<400> SEQUENCE: 4 
ataacgctgc tgctgggtc 
<210> SEQ ID NO 5 
<211> LENGTH: 23 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: TBDDLEXF PRIMER 
<400> SEQUENCE: 5 
cgggatccgt gagtgctaac gac 
<210> SEQ ID NO 6 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: TBDDLEXR PRIMER 
<400> SEQUENCE: 6 
cggaagcttg tgccgatcgc aagc 
<210> SEQ ID NO 7 
<211> LENGTH: 21 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: SMDDLPE PRIMER 
<400> SEQUENCE: 7 
aaacgctccg gatcgaggtt g 
<210> SEQ ID NO 8 
<211> LENGTH: 18 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: TBDDLPE PRIMER 
<400> SEQUENCE: 8 
gagatggcgt gctcgttg 
What is claimed and desired to be secured by Letters 
Patent is as follows: 
1. A recombinant plasmid pBUN276 on deposit with the 
American Type Culture Collection as accession number 
PTA-8190. 
2. A transformed microorganism comprising the plasmid 
of claim 1. 
3. The transformed microorganism of claim 2, wherein the 
microorganism is a naturally occurring or genetically modi- 
fied mycobacterium strain selected from the group consist- 
ing of M. smegmatis, M. tuberculosis, M. bovis, M. afri- 
canum, M. microti, M. leprae, M. avium, M. intracellular, M. 
55 
paratuberculosis, M. ulcerans, M. marinum, and any sub- 
species of said mycobacterium strains. 
4. The transformed microorganism of claim 2, wherein the 
transformed microorganism is recombinant mycobacterium 
60 strain GPM265. 
5. A recombinant plasmid, comprising at least one 
genomic DNA fragment encoding M. tuberculosis Ddl, said 
at least one DNA fragment fused in frame with the first six 
codons of M. bovis BCG hsp60 gene, and operably linked to 
65 the promoter of the M. bovis BCG hsp60 gene, wherein said 
at least one DNA fragment is cloned into an E. coli- 
mycobacterium shuttle vector. 
US 7,371,571 B2 
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6. A method for producing a recombinant microorganism (a) exposing a culture of the recombinant mycobacterium 
comprising: transforming a mycobacterium with the plasmid strain of claim 4 to an agent to be tested to form a test 
of claim 1, and selecting, in the presence of kanamycin, the culture; and 
recombinant microorganism. (b) comparing the D-alanine ligase activity of the test 
5 culture with the D-alanine ligase activity of a control 7. The method of claim 6, wherein the mycobacterium is 
culture of the recombinant mycobacterium strain of 
transformed by electroporation. claim 4 in the absence of the agent, 
- 
8. Amethod of producing a microorganism with an altered wherein less D-alanine ligase activity in the test culture 
level of D-alanine ligase expression relative to the corre- than in the control culture is indicative of inhibition of 
sponding non-transformed microorganism, comprising l o  D-alanine ligase activity by the agent. 
transforming the microorganism with the plasmid of claim 1. 10. The method of claim 9, wherein the agent is an 
9. A method of screening for agents which inhibit D-ala- agent. 
nine ligase activity, comprising: * * * * *  
